Terns Pharmaceuticals – 2025-11-17 - Increase Confidence 8/10

TERN – increase in Days/Weeks

Terns Pharmaceuticals reported negative free cash flow of $70 million TTM, reflecting heavy investment in R&D, which surged to $19.9 million in Q3 2025 YoY. This financial commitment coincides with the release of positive Phase 1 CML data for TERN-701 and an upcoming oral presentation at ASH 2025, serving as a key near-term catalyst.

Why This Matters

The biotech market prices stocks on binary clinical outcomes, not profitability, and Terns’ decision to streamline its pipeline toward oncology—while preserving cash into 2028—positions TERN-701 as a high-upside asset. With institutional holders like Orbimed and Vivo Capital signaling confidence, and management de-risking by partnering out metabolic programs, capital is now focused on a single, potentially best-in-disease oncology candidate, amplifying the market impact of upcoming data.

Key Insights

• R&D Spend: $19.9 million in Q3 2025, up from $15.2 million YoY, signaling prioritization of TERN-701
• News Impact: ASH 2025 oral presentation of expanded TERN-701 data → potential 20–30% upside on positive readout
• Risk/Offset: Pipeline narrowing increases event concentration risk; failure could trigger 40%+ downside

Practical Implications

• Bull Case: Positive ASH oral data → rapid re-rating to $32–$35 range on best-in-class BCR-ABL inhibitor potential
• Bear Case: Data disappointment or safety signals → drop to $18–$20, especially if partnership talks stall
• Confidence: 8/10 – High-impact catalyst imminent, strong cash position, and focused strategy support upside

Prediction: increase

Reference:

• https://markets.businessinsider.com/news/stocks/terns-pharmaceuticals-reports-third-quarter-2025-financial-results-and-provides-corporate-updates-1035536168